Abstract |
The cytotoxic drug mitozolomide has been found to cause unpredictably severe thrombocytopenia during phase I and II clinical trials. In an attempt to relate dose and pharmacokinetic parameters to toxicity, we measured plasma concentrations of mitozolomide in 14 patients with a range of malignancies. There were significant correlations (Spearman rank correlation test) between drug clearance and AUC and white blood cell nadir. The pharmacokinetic and toxicity data were not normally distributed; therefore, it was not possible to construct predictive nomograms for toxicity based on linear regression analysis.
|
Authors | D J Kerr, J A Slack, P Secrett, M F Stevens, G R Blackledge, C Bradley, S B Kaye |
Journal | Cancer chemotherapy and pharmacology
(Cancer Chemother Pharmacol)
Vol. 25
Issue 5
Pg. 352-4
( 1990)
ISSN: 0344-5704 [Print] Germany |
PMID | 2306796
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Nitrogen Mustard Compounds
- mitozolomide
|
Topics |
- Adult
- Aged
- Antineoplastic Agents
(adverse effects, pharmacokinetics)
- Female
- Humans
- Leukocyte Count
- Male
- Middle Aged
- Nitrogen Mustard Compounds
(adverse effects, pharmacokinetics)
- Platelet Count
|